Durable Survival Outcomes in Advanced Melanoma With Neoadjuvant Dual Immunotherapy

(MedPage Today) — The vast majority of patients with stage III resectable melanoma treated with neoadjuvant and adjuvant dual immunotherapy — nivolumab (Opdivo) and relatlimab (Opdualag) — remained alive and disease-free after almost 4 years…

Source link : https://www.medpagetoday.com/oncology/skincancer/116494

Author :

Publish date : 2025-07-14 18:45:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Durable Survival Outcomes in Advanced Melanoma With Neoadjuvant Dual Immunotherapy

Downstream Effects

Kidney Transplantation Without Lifelong Immunosuppression Edges Toward Reality

Related Posts

CDC Gunman Blamed His Depression on the COVID Vaccine: Here’s What the Research Says

When to Refer Pediatric Allergic Rhinitis From Primary Care

Fourth Person Dies in Legionnaires’ Disease Outbreak: Here’s What to Know

President Trump Wants to Undo EPA’s Ability to Protect Our Climate and Air

Oldest fast radio burst ever seen sheds light on early star formation

MAHA Report Leaked; ACIP Member’s ‘Violent Rhetoric’; Cholera Outbreak

CDC Gunman Blamed His Depression on the COVID Vaccine: Here’s What the Research Says

When to Refer Pediatric Allergic Rhinitis From Primary Care

Fourth Person Dies in Legionnaires’ Disease Outbreak: Here’s What to Know

President Trump Wants to Undo EPA’s Ability to Protect Our Climate and Air

Oldest fast radio burst ever seen sheds light on early star formation

MAHA Report Leaked; ACIP Member’s ‘Violent Rhetoric’; Cholera Outbreak

AI Detects Missed Interval Breast Cancer on Mammograms

We have detected a single electron with unprecedented speed

Categories

Archives